Astrazeneca Ab

Gary Steelman

Rebecca Urbanek

Abdelmalik Slassi

Methvin Benjamin Isaac

Thomas Michael Bare

Bradford C Van Wagenen

Fupeng Ma

Ian Egle

Joshua Clayton

James Empfield

Dean Brown

Megan Murphy

Wenhua Xiao

Radhakrishnan Ukkiramapandian

Sally Walsh

Carey Horchler

Edward Vacek

Christine Barlaam

Frances Marie McLaren

Vernon Alford

Suzanne J Suchard

Marc Chapdelaine

Katherine Knappenberger

Linda Sygowski

Chris Allan Veale

Compounds of formula I: wherein R, R, R, R, R, R, R, R, Rand n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.

Metabotropic glutamate-receptor-potentiating isoindolones

The present invention is directed to compounds of formula I: wherein R, R, R, R, R, R, R, R, Rand n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Substituted isoindolones and their use as metabotropic glutamate receptor potentiators

Compounds according to structural diagram (I) The following is an examiner's statement of reasons for allowance: In view of applicants' amendments to the claims which limit 'E' to phenyl or cycloalkyl groups the rejections of the previous action no longer pertain as they at best teach 'E' as alkyl.

1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain

Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Qat each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C-C) alkyl and C(O)phenyl, and Qis selected from hydrogen, halogen, O&#x2014;(C-C)alkyl, O&#x2014;(C-C)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NOor halogen, and indolyl may be substituted with (C-C)alkyl or phenyl

Cd45 inhibitors

A compound, 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione, its (&#x2212;) enantiomer, its (+) enantiomer, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administering a pain-ameliorating effective amount of the (&#x2212;) enantiomer to an individual suffering from pain and pharmaceutical compositions containing the (&#x2212;) enantiomer are disclosed.

7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain

Compounds useful for the treatment of pain in accord with structural diagram (I), or tautomers or pharmaceutically-acceptable salts of such compounds, wherein R and A are as disclosed in the specification. Also disclosed are methods for the treatment of pain using compounds according to structural diagram (I) and pharmaceutical compositions comprising compounds according to structural diagram (I).

1, 2, 5, 10-tetrahydropyridazino&lsqb;4, 5-b&rsqb;quinoline-1,10-diones and their use for the treatment of pain

Compounds and methods for the treatment of pain

Growing community of inventors

Wilmington, DE, United States of America

Gary Steelman